Peritoneal Cancer Market

The global peritoneal cancer market was valued at USD 1.2 billion in 2025 and is estimated at USD 1.3 billion in 2026. The market is projected to reach USD 2.3 billion by 2034, representing a 7.3% CAGR during 2026–2034.

Peritoneal malignancy treatment combines care for primary peritoneal carcinoma with selected peritoneal surface metastases arising from ovarian, colorectal, appendiceal, gastric and other primary tumors. The counted market includes disease-attributable systemic antineoplastic drugs, cytoreductive surgery, hyperthermic intraperitoneal chemotherapy and other specialized peritoneal interventions. A treatment episode is allocated to its principal intervention, while companion diagnostic testing and general oncology expenditure outside the peritoneal indication are excluded. This boundary avoids counting the entire ovarian or colorectal drug market as peritoneal cancer revenue.

Primary peritoneal carcinoma resembles epithelial ovarian cancer in pathology and treatment. The National Cancer Institute groups ovarian epithelial, fallopian tube and primary peritoneal cancers because their shared M - llerian origin supports comparable staging and therapeutic pathways. Platinum-based chemotherapy and cytoreductive surgery remain central for suitable patients, with maintenance PARP inhibition and biomarker-directed antibody-drug conjugates serving defined populations. For peritoneal metastases from gastrointestinal tumors, resectability, tumor burden and referral to experienced surgical teams influence which interventions are clinically appropriate.

The FDA granted full approval to AbbVie's mirvetuximab soravtansine in March 2024 for folate receptor-alpha-positive platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. In the MIRASOL study, median overall survival was 16.5 months with the antibody-drug conjugate versus 12.7 months with investigator-selected chemotherapy. Later decisions expanded choices: pembrolizumab with paclitaxel entered a PD-L1-selected recurrent setting in February 2026, and relacorilant with nab-paclitaxel was approved in March 2026 after prior bevacizumab exposure.

Revenue growth reflects both medicine eligibility and the capacity to deliver complex procedures. The NCI describes heated intraperitoneal chemotherapy as an experimental approach in high-grade serous ovarian cancer, despite randomized evidence in selected interval-debulking patients. NICE recommended mirvetuximab for eligible NHS patients in June 2026, while European and Australian regulatory pathways have widened access to the same agent. Availability remains uneven because biomarker testing, surgical expertise, drug funding and toxicity monitoring must align before an individual patient can receive a particular regimen.

Source: NCI primary peritoneal cancer treatment; FDA mirvetuximab full approval; FDA pembrolizumab ovarian/peritoneal approval; NICE mirvetuximab appraisal.

The market measures disease-attributable revenue from systemic antineoplastic medicines, cytoreductive procedures and specialized intraperitoneal interventions used for primary peritoneal carcinoma or confirmed peritoneal surface malignancy. The same patient may receive several therapies, but each paid product or intervention is counted once in its relevant category.

Drivers Impact Analysis*

Restraints Impact Analysis*

*CAGR contribution shows the percentage points each factor adds to or removes from the 7.3% CAGR for 2026–2034; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.

New biomarker-defined options expand recurrent treatment choices

The FDA granted full approval to mirvetuximab soravtansine for FR?-positive platinum-resistant disease in March 2024. Subsequent approval of pembrolizumab with paclitaxel for PD-L1 CPS-positive recurrent disease in February 2026 introduced a different selection pathway. These indications include primary peritoneal carcinoma alongside ovarian and fallopian tube cancers, creating additional prescribing options after prior treatment. Their uptake still depends on pathology results, prior regimen history and management of adverse events rather than broad use in all patients.

Specialized surgery and HIPEC create capacity-sensitive demand

Cytoreductive surgery is established in selected ovarian and peritoneal surface malignancies, while HIPEC requires perfusion systems, experienced teams and strict case selection. The NCI describes a Dutch randomized trial of 245 patients undergoing interval surgery, with final median overall survival of 44.9 months in the HIPEC arm and 33.3 months after surgery alone. This evidence informs referral discussions but does not establish routine use for every peritoneal cancer histology. Center capacity and patient fitness constrain the number of procedures delivered.

Regional authorization broadens availability beyond US centers

European authorization of Elahere in November 2024 and Australian registration in February 2026 expanded potential access to FR?-selected treatment. The United Kingdom separately authorized the medicine in July 2025 and NICE recommended NHS funding in June 2026. Brazil registered the product in September 2025. These decisions can increase eligible patient access, but national reimbursement, biomarker laboratory capacity and local oncology guidelines determine the timing and scale of actual treatment uptake. A newly authorized medicine may therefore contribute to revenue at different rates in the United States, Europe and Latin America.

Toxicity and reimbursement narrow realized treatment volumes

Mirvetuximab carries ocular toxicity warnings, requiring ophthalmic assessment and monitoring, while relacorilant with nab-paclitaxel requires attention to neutropenia, infection and adrenal effects. NICE tied its positive mirvetuximab recommendation to a commercial access arrangement. Patients without specialist referral or approved molecular testing may not reach the indicated therapies despite regulatory authorization. Budget constraints also affect access to complex cytoreduction and heated perfusion, where costs include operating time, disposables and inpatient resources. These practical requirements can delay treatment even when the patient meets the clinical label.

Combination sequencing changes the value of each treatment line

The March 2026 approval of relacorilant with nab-paclitaxel followed a trial requiring previous bevacizumab exposure, whereas the pembrolizumab regimen requires PD-L1 CPS at least one and limited prior lines. These restrictions mean the products serve overlapping but nonidentical patient groups. PARP maintenance after platinum response and later antibody-drug conjugate treatment add distinct care phases. Revenue expansion therefore depends on the number of qualifying episodes, duration of therapy and sequencing decisions, not merely on the count of approved products.

NCI peritoneal cancer treatment; FDA Elahere, Keytruda and Lifyorli approvals; EMA and NICE access decisions.

FR?-directed ADC therapy reaches more national health systems

Elahere received European authorization in November 2024 and United Kingdom approval in July 2025 for selected platinum-resistant ovarian, fallopian and primary peritoneal cancers. NICE recommended the medicine in June 2026 for eligible patients in England, while Australia and Brazil also registered the product. The relevant commercial population depends on FR? testing and prior lines of treatment. Growth in use is likely to differ by country because oncology formulary processes and ocular monitoring resources are not uniform.

Immunotherapy eligibility becomes more dependent on pathology

The February 2026 US approval of pembrolizumab with paclitaxel requires PD-L1 CPS of at least one, determined using an authorized test. Agilent announced US clearance of its 22C3 pharmDx assay in February and European certification in July 2026 for the same cancer group. This creates a linked diagnostic and therapeutic pathway for recurrent disease. Testing quality and turnaround time affect whether oncologists can identify eligible patients before a subsequent treatment decision becomes necessary. For PD-L1 eligibility in 2026, laboratories need trained pathologists and validated quality-control procedures for the 22C3 assay.

HIPEC use remains selective despite long-term surgical evidence

The NCI ovarian cancer treatment summary reviews a randomized Dutch study involving 245 patients assigned to interval cytoreduction with or without heated intraperitoneal cisplatin. Survival differences support continued evaluation, yet the NCI still characterizes HIPEC as experimental in high-grade serous ovarian cancer. Manufacturers including RanD and ThermaSolutions supply perfusion equipment for specialist centers. The technology trend therefore concerns protocol standardization, trained personnel and carefully selected surgical candidates rather than universal adoption across metastatic disease. In the NCI-reviewed interval-surgery trial, postoperative recovery and treatment-related complications remained important parts of patient selection.

Treatment sequencing expands after platinum resistance

The FDA approved relacorilant with nab-paclitaxel in March 2026 after ROSELLA demonstrated improved progression-free and overall survival versus nab-paclitaxel alone. The label requires prior bevacizumab, distinguishing its population from the FR?-selected Elahere group and the PD-L1-selected pembrolizumab combination. Clinical teams increasingly assess biomarker status, previous toxicity and the time since platinum treatment together. That sequencing complexity may support more individualized care while limiting the volume available to any single therapy. Prior treatment records are necessary to apply the label correctly.

Intervention Type assigns peritoneal cancer revenue to the principal paid modality. Systemic medicines, cytoreductive surgery, heated intraperitoneal perfusion and other localized approaches are mutually exclusive categories. Combination courses allocate individual payments once without treating the same operation as a separate duplicate service.

Systemic therapy supplies the broadest recurring expenditure, whereas surgery and HIPEC depend on concentrated institutional capability. Care pathways increasingly combine molecular testing with resectability assessment and prior-treatment history, so the distribution of spending changes as new regimens reach reimbursed practice.

Disease Origin separates primary peritoneal and M - llerian-type disease from peritoneal dissemination arising in gastrointestinal or other primary tumors. The allocation uses the clinically assigned origin and does not count an ovarian or colorectal patient again under a second primary. Treatment strategies differ materially by histology and extent of spread.

The leading ovarian and primary peritoneal segment benefits from directly applicable regulatory labels. Secondary peritoneal disease contributes substantial referral and procedural activity, but case selection is more heterogeneous and requires tumor-origin-specific evidence rather than a single universal treatment protocol.

Treatment Phase classifies revenue by the clinical point at which the relevant medicine or procedure is delivered. Newly diagnosed disease, platinum-sensitive or surgically resectable recurrence, and resistant or advanced disease form nonoverlapping categories for each treatment episode. A patient can move between phases over time, but an individual course is assigned once.

Phase-specific revenue depends on the number of eligible treatment courses and the duration of each regimen. Resistance, cumulative toxicity and changing functional status can reduce later-line uptake even when several medicines hold authorization for selected patient populations.

Care Setting attributes revenue to the institution responsible for delivering the treatment or procedure. Tertiary oncology hospitals, specialist peritoneal surgery centers, community oncology networks and research facilities form exclusive provider categories. Patients may be referred between institutions, but revenue is assigned according to the actual delivery site for each billed service.

Institutional shares depend on local payment structures and referral concentration. Expansion of community drug delivery may improve access, but high-risk surgery and specialized perfusion will continue to require experienced centers with multidisciplinary governance and perioperative support.

Regional spending reflects differences in specialty surgical capacity, access to biomarker-selected medicines, oncology reimbursement and the availability of peritoneal malignancy referral pathways. Modeled 2025 regional allocations are independent of disease incidence and are not audited manufacturer sales shares.

Competition in the peritoneal cancer market spans pharmaceutical manufacturers, molecular diagnostic suppliers and companies providing specialized surgical perfusion equipment. These participants do not sell interchangeable products: drug eligibility is determined by tumor biology and prior treatment, whereas HIPEC devices serve a selected procedural population. The most visible recent commercial changes concern FR?-directed therapy, PD-L1-selected immunotherapy and relacorilant combinations for recurrent disease.

AstraZeneca participates through olaparib maintenance indications that include primary peritoneal cancer, and GSK markets niraparib for selected advanced ovarian, fallopian and peritoneal disease. Roche's bevacizumab is used with chemotherapy in several eligible settings. These established treatments can be sequenced with newer agents according to biomarker results and prior exposure. Competitive positioning depends on treatment-line evidence and reimbursement rather than a uniform peritoneal cancer product category.

Daiichi Sankyo is developing a CDH6-directed antibody-drug conjugate with Merck for platinum-resistant ovarian cancer, an investigational program that should not be counted as an approved peritoneal indication. Corcept's ROSELLA results and AbbVie's MIRASOL data demonstrate how randomized evidence can support label expansion. Trial eligibility may combine ovarian, fallopian and primary peritoneal populations, so commercial attribution requires disease-specific allocation rather than assigning all reported oncology sales to peritoneal malignancy.

Specialized procedure suppliers compete on hospital technology requirements rather than drug labels. RanD and ThermaSolutions offer equipment for controlled intraperitoneal heating and perfusion, with adoption tied to hospital capital budgets, trained staff and clinical protocols. Agilent and Roche Diagnostics supply patient-selection assays that can influence medicine eligibility. Hospitals must coordinate surgery, pathology, pharmacy and supportive care; a manufacturer can gain market access without immediately achieving high utilization if any part of that pathway is unavailable.

• AbbVie Inc.
• Merck & Co., Inc.
• Corcept Therapeutics Incorporated
• AstraZeneca PLC
• GSK plc
• F. Hoffmann-La Roche Ltd
• Agilent Technologies, Inc.
• RanD S.p.A.
• ThermaSolutions, Inc.
• Daiichi Sankyo Company, Limited

From 2026 to 2034, peritoneal cancer treatment demand will reflect the balance between additional biomarker-defined regimens, specialized surgical capacity and the constraints of late-stage disease. The projected 7.3% CAGR is a market-wide outlook, not an assertion that every product class or country will expand at the same pace.

Systemic medicine growth will be influenced by the populations defined in the FDA's 2026 approvals. Pembrolizumab requires PD-L1 CPS positivity and specified prior therapy, while relacorilant requires earlier bevacizumab exposure. Mirvetuximab remains restricted to FR?-positive disease and carries ocular safety obligations. These differences support multiple commercial pathways but limit direct substitution. Manufacturers must fund testing partnerships and pharmacovigilance alongside distribution; the size of the eligible treated population matters more than the total number of patients with abdominal cancer.

Surgery will remain important for patients whose disease distribution and fitness support cytoreduction. The NCI describes randomized evidence for heated intraperitoneal cisplatin at interval surgery in ovarian cancer, but also notes unresolved questions about routine HIPEC use in high-grade serous disease. Equipment suppliers may benefit from selective hospital investment, training and disposable consumption. Commercial forecasts should not treat every patient with peritoneal spread as a candidate for heated perfusion, because tumor origin and completeness of possible resection are decisive.

Regional expansion will differ as regulators and national payers make separate access decisions. NICE's June 2026 mirvetuximab recommendation supports NHS access in England, while Brazil and Australia have granted regulatory authorization. The European Medicines Agency's September 2026 positive opinion on relacorilant marks a separate stage of review rather than guaranteed reimbursement. North American centers may adopt new regimens sooner because of established diagnostic networks, but payer restrictions and toxicity monitoring still affect uptake. Emerging markets require affordable testing and specialist referrals before new labels translate into sustained treatment volume.

Risks include late diagnosis, high recurrence, incomplete resection, cumulative treatment toxicity and uneven drug funding. The NCI's clinical summary groups primary peritoneal carcinoma with ovarian epithelial cancer but does not support applying every ovarian treatment to all secondary peritoneal malignancies. Competitive trials may displace existing regimens rather than add entirely new spending. The 2034 projection therefore depends on treatment-line sequencing, evidence quality, patient eligibility and net realized prices, with care delivery constrained by specialized staff and hospital capacity.

Coverage includes peritoneal-directed oncology medicines, cytoreductive surgery, HIPEC equipment and procedures, disease-origin differences, patient treatment phases, specialist care settings, regional access and the 2026–2034 forecast.